Ozempic vs Trulicity: Real-World Evidence Comparison

What the Head-to-Head Trial Says

SUSTAIN-7 is the only large randomized controlled trial comparing semaglutide directly against dulaglutide. It enrolled 1,201 adults with type 2 diabetes inadequately controlled on metformin and randomized them to one of four arms: semaglutide 0.5 mg, semaglutide 1.0 mg, dulaglutide 0.75 mg, or dulaglutide 1.5 mg, all given once weekly for 40 weeks.

A1C Reductions at 40 Weeks

Semaglutide 0.5 mg reduced A1C by 1.5% versus 1.1% for the dose-matched dulaglutide 0.75 mg arm (P<0.001). At the higher doses, semaglutide 1.0 mg reduced A1C by 1.8% compared with 1.4% for dulaglutide 1.5 mg (P<0.001). Both differences were statistically significant and clinically meaningful. The American Diabetes Association's 2024 Standards of Care define a clinically relevant A1C change as 0.5% or greater, so both comparisons crossed that threshold. [1]

Weight Loss Differences

The weight outcomes were even more pronounced. Semaglutide 0.5 mg produced a mean loss of 4.6 kg versus 2.3 kg for dulaglutide 0.75 mg. At the higher doses, semaglutide 1.0 mg patients lost 6.5 kg versus 3.0 kg for dulaglutide 1.5 mg. That 3.5 kg difference at the 1.0 mg vs 1.5 mg comparison is not trivial. For a 90 kg patient, it represents nearly a full percentage point of body weight. [1]

Gastrointestinal Tolerability

Nausea rates were modestly higher with semaglutide in SUSTAIN-7: 17.2% for semaglutide 1.0 mg vs 12.2% for dulaglutide 1.5 mg. Vomiting rates followed a similar pattern. Most events were transient and occurred during dose escalation. Discontinuation due to GI adverse events was below 5% in both groups. [1]

Cardiovascular Outcomes: Two Different Trials, Two Different Questions

Neither SUSTAIN-7 nor any other single trial has compared the cardiovascular effects of semaglutide and dulaglutide head-to-head. Each drug has its own dedicated CVOT (cardiovascular outcomes trial), and comparing across them requires caution because the patient populations differed.

SUSTAIN-6: Semaglutide's CVOT

SUSTAIN-6 enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk (83% with established CV disease). Over a median 2.1 years, semaglutide 0.5 mg and 1.0 mg combined reduced the three-point MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 26% relative to placebo (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority, P=0.02 for superiority). The benefit was driven almost entirely by a 39% reduction in nonfatal stroke. [2]

REWIND: Dulaglutide's CVOT

REWIND enrolled 9,901 patients, a meaningfully larger cohort, with a lower cardiovascular risk profile than SUSTAIN-6. Only 31% had established cardiovascular disease at baseline. Dulaglutide 1.5 mg reduced the primary MACE endpoint by 12% relative to placebo over a median 5.4 years (HR 0.88, 95% CI 0.79 to 0.99, P=0.026). [3]

The Lancet publication stated: "Dulaglutide could be considered for the reduction of cardiovascular events in middle-aged and older people with type 2 diabetes who have either established cardiovascular disease or cardiovascular risk factors." [3]

Because REWIND enrolled a primary-prevention population at meaningful scale, dulaglutide's label includes a broader CV indication than semaglutide's. For patients without established cardiovascular disease who still carry moderate CV risk, dulaglutide has randomized trial support that semaglutide currently does not match in that specific subgroup.

Real-World Evidence: Beyond the RCTs

Randomized trials control for adherence and titration schedules in ways that clinical practice does not. Several large observational datasets fill the gap.

US Claims Data

A 2021 analysis of IBM MarketScan and Optum databases covering more than 35,000 GLP-1 initiators found that patients starting semaglutide achieved A1C reductions approximately 0.3 to 0.5% greater than those starting dulaglutide at 12 months, after propensity-score adjustment for baseline A1C, age, BMI, and prior therapy. Weight loss differences were proportionally larger, with semaglutide patients averaging 2.1 kg more loss at one year. Adherence at 12 months did not significantly differ between agents. [4]

European Registry Data

The EXPERT registry, which tracked over 6,000 GLP-1-naive patients across 10 European countries, reported A1C reductions and body weight outcomes consistent with SUSTAIN-7 in the real-world setting. Semaglutide-treated patients achieved target A1C below 7.0% at a rate of 47% compared with 32% for dulaglutide-treated patients at 12 months of follow-up. [5]

Injection Device Preference

Real-world persistence data show that device design affects adherence. The Trulicity autoinjector hides the needle entirely and requires no priming, which some patients find less intimidating. The Ozempic pen uses a dial mechanism and a visible needle cap. In a 2022 survey of 1,804 GLP-1 users published in Diabetes Technology and Therapeutics, 61% of respondents rated needle-hidden autoinjectors as "strongly preferred" over traditional pen injectors. Whether this preference translates into measurable adherence differences in large claims datasets remains mixed across studies. [6]

Dosing, Titration, and Practical Differences

Ozempic Dose Escalation Schedule

Ozempic begins at 0.25 mg weekly for 4 weeks (a tolerability dose, not a therapeutic dose), then advances to 0.5 mg weekly. If additional glycemic control is needed after at least 4 weeks at 0.5 mg, the dose increases to 1.0 mg. Since 2022, the FDA-approved maximum dose is 2.0 mg weekly, supported by the SUSTAIN FORTE trial, which showed 2.0 mg reduced A1C by 2.2% from a baseline of 8.9% over 40 weeks. [7]

Trulicity Dose Escalation Schedule

Trulicity starts at 0.75 mg weekly for at least 4 weeks, then advances to 1.5 mg weekly. In 2020, the FDA approved higher doses of 3.0 mg and 4.5 mg weekly (AWARD-11 trial data). AWARD-11 showed that 4.5 mg dulaglutide reduced A1C by 1.77% versus 1.54% for the 1.5 mg dose. The higher dulaglutide doses narrow the efficacy gap with semaglutide somewhat, though direct comparisons at maximal doses have not been conducted in an RCT. [8]

Renal and Hepatic Considerations

Neither agent requires dose adjustment for renal impairment, and both are considered safe in patients with eGFR as low as 15 mL/min/1.73 m², based on current FDA labeling. This is a meaningful advantage of the GLP-1 class over sulfonylureas and some older agents. Both agents are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. [9]

Which Drug Performs Better for Weight Loss?

Weight loss is the clearest domain where semaglutide wins. This applies to both diabetes-dose semaglutide (Ozempic) and the 2.4 mg obesity dose (Wegovy). Trulicity is not FDA-approved for weight management.

At the diabetes doses studied in SUSTAIN-7, semaglutide 1.0 mg produced 2.2 times the weight loss of dulaglutide 1.5 mg (6.5 kg vs 3.0 kg). Real-world claims data largely replicate this margin. For patients with type 2 diabetes who also need significant weight reduction, semaglutide is the more appropriate agent. [1]

For patients who are primarily seeking glycemic control with modest weight targets and who have a strong preference for the Trulicity autoinjector, the choice is more nuanced. Dulaglutide at 4.5 mg may close some of the efficacy gap, though no head-to-head trial with semaglutide 2.0 mg exists.

The HealthRX clinical team uses a simple three-question decision framework when selecting between these two agents:

1. Does the patient need more than 4% body weight loss? If yes, semaglutide is preferred.
2. Does the patient have established CV disease and a history of prior GI intolerance on semaglutide? If yes, dulaglutide 1.5 to 4.5 mg is a reasonable alternative.
3. Is the patient primarily prevention-focused with moderate CV risk and no weight priority? Either agent is acceptable; dulaglutide's REWIND data are specifically relevant here.

Switching from Trulicity to Ozempic

Who Should Consider Switching

Patients currently on Trulicity who have not reached A1C target despite 12 weeks at the 1.5 mg or higher dose may benefit from switching to semaglutide. Real-world data from the US and Europe show that switching from any non-semaglutide GLP-1 to semaglutide produces additional A1C reductions of 0.3 to 0.7% and additional weight loss of 1.5 to 3.0 kg at six months. [4]

How to Switch

No washout period is required. Patients on Trulicity can start Ozempic at the 0.25 mg tolerability dose the week following their last Trulicity injection, or they may start Ozempic at 0.5 mg if they have already demonstrated GLP-1 tolerability on Trulicity. The treating clinician should assess GI symptoms at the 4-week and 8-week follow-up visits after the switch.

Who Should Not Switch

Patients who achieved adequate A1C control on Trulicity with good tolerability and are also using it for its established CV risk reduction benefit (particularly those in a primary-prevention cardiovascular context mirroring the REWIND population) may not benefit from a switch purely for weight or A1C reasons. Stability on an effective regimen has its own value.

Safety Profile Side-by-Side

Both semaglutide and dulaglutide carry a class-level FDA boxed warning for thyroid C-cell tumors based on rodent data, and both share the core GLP-1 safety profile. The key differences are:

Pancreatitis. Both agents carry a precaution for pancreatitis. A 2023 meta-analysis of 13 GLP-1 RCTs covering over 90,000 patient-years found no statistically significant increase in acute pancreatitis with GLP-1 receptor agonists as a class compared with placebo or active comparators. [10]

Diabetic retinopathy. Semaglutide's SUSTAIN-6 showed a 76% relative increase in diabetic retinopathy complications (HR 1.76, 95% CI 1.11 to 2.78) in patients with pre-existing retinopathy who experienced rapid A1C reduction. REWIND did not replicate this signal for dulaglutide. Clinicians should assess baseline retinopathy before starting Ozempic in patients with long-standing, poorly controlled diabetes. [2]

Gallbladder disease. Both agents are associated with an increased rate of cholelithiasis. A pooled analysis of semaglutide trials found approximately a 1.1% absolute increase in gallbladder-related events over placebo. [11]

Injection-site reactions. Both agents cause injection-site reactions in roughly 1 to 2% of patients. Neither has a meaningful advantage here.

Cost and Access

List prices for both agents sit near $900, $1,000 per month in the US without insurance, though effective costs depend heavily on insurer formulary placement and manufacturer savings programs. As of 2024, Trulicity has a longer market history (approved 2014 vs 2017) and in some commercial formularies carries a lower tier placement than Ozempic. Novo Nordisk's Ozempic savings card reduces out-of-pocket cost to $25/month for eligible commercially insured patients, and Eli Lilly offers comparable savings for Trulicity. Neither drug has a generic equivalent currently available in the US. [12]

Pregnancy, Pediatrics, and Special Populations

Pregnancy

Neither agent is recommended during pregnancy. The FDA classifies both as Category not assigned under the new labeling system, but both manufacturers advise discontinuing at least 2 months before planned conception due to the extended half-life of semaglutide (approximately 7 days) and the potential for fetal harm observed in animal studies. [9]

Pediatric Use

Semaglutide (Ozempic) gained FDA approval for type 2 diabetes in patients aged 10 years and older in December 2022. Dulaglutide does not currently have pediatric approval in the US. For adolescents with type 2 diabetes, semaglutide is the only agent in this class with an approved pediatric indication. [9]

Older Adults

REWIND enrolled adults with a mean age of 66 years and included patients up to age 80. This makes REWIND particularly relevant for the older adult population. Semaglutide's trial populations were somewhat younger on average. Both agents are generally well tolerated in older adults, though appetite suppression and nausea warrant monitoring for unintended weight loss and muscle mass reduction in patients already at nutritional risk.

Summary Table: Ozempic vs Trulicity at a Glance

| Feature | Ozempic (Semaglutide) | Trulicity (Dulaglutide) | |---|---|---| | Doses available | 0.5, 1.0, 2.0 mg weekly | 0.75, 1.5, 3.0, 4.5 mg weekly | | A1C reduction (highest dose) | , 2.2% (2.0 mg, SUSTAIN FORTE) | , 1.77% (4.5 mg, AWARD-11) | | Mean weight loss (highest dose) | , 6.5 kg (1.0 mg, SUSTAIN-7) | , 3.0 kg (1.5 mg, SUSTAIN-7) | | MACE reduction vs placebo | 26% (SUSTAIN-6) | 12% (REWIND) | | CV primary prevention data | Limited | Yes (REWIND, 69% no prior CVD) | | Pediatric approval (T2D) | Yes (age 10+) | No | | Device type | Prefilled dial pen | Single-use autoinjector | | Retinopathy signal | Yes (in rapid A1C reducers) | Not observed in REWIND |